Detailed Pathophysiology of Minimal Change Disease: Insights into Podocyte Dysfunction, Immune Dysregulation, and Genetic Susceptibility
Open Access
- 13 November 2024
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (22) , 12174
Abstract
Minimal Change Disease (MCD) is a predominant cause of idiopathic nephrotic syndrome in the pediatric population, yet presents significant clinical challenges due to its frequent relapses and steroid resistance. Despite its relatively benign histological appearance, MCD is characterized by severe proteinuria, hypoalbuminemia, and edema, which may affect patient outcomes. Current treatment strategies primarily rely on corticosteroids, which are effective in inducing remission but are associated with high relapse rates, steroid resistance, and numerous long-term side effects, underscoring the need for more targeted and effective therapeutic approaches. This narrative review synthesizes current knowledge on the pathophysiological mechanisms underlying MCD, focusing on the following three critical areas: podocyte dysfunction, immune dysregulation, and genetic susceptibility. Podocyte dysfunction, particularly involving alterations in nephrin, plays a central role in the breakdown of the glomerular filtration barrier, leading to the characteristic proteinuria observed in MCD. Immune dysregulation, including the presence of autoantibodies against nephrin and other podocyte components, exacerbates podocyte injury and contributes to disease progression, suggesting an autoimmune component to the disease. Genetic factors, particularly mutations in the NPHS1 and NPHS2 genes, have been identified as significant contributors to disease susceptibility, influencing the variability in treatment response and overall disease severity. Understanding these mechanisms is crucial for developing targeted therapies that address the underlying causes of MCD rather than merely managing its symptoms. This review highlights the need for further research into these pathophysiological processes to pave the way for more personalized and effective treatment strategies, ultimately improving patient outcomes and reducing reliance on corticosteroids.Keywords
Funding Information
- Medical University of Lodz (503/1-151-02/503-11-001)
This publication has 96 references indexed in Scilit:
- IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndromePediatric Nephrology, 2022
- The potential of RNA-based therapy for kidney diseasesPediatric Nephrology, 2022
- Efficacy and safety of tacrolimus versus corticosteroid as initial monotherapy in adult-onset minimal change disease: a meta-analysisInternational Urology and Nephrology, 2022
- New insight into podocyte slit diaphragm, a therapeutic target of proteinuriaClinical and Experimental Nephrology, 2020
- Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanismsPediatric Nephrology, 2016
- CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significancePediatric Nephrology, 2013
- The Gne M712T Mouse as a Model for Human GlomerulopathyThe American Journal of Pathology, 2012
- Idiopathic Nephrotic Syndrome: Genetic Aspects2009
- Corticosteroid therapy for nephrotic syndrome in children2005
- Expression of nephrin in acquired forms of nephrotic syndrome in childhoodPediatric Nephrology, 2004